Benjamin A. Teply

Also affiliated with Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma”.

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma

JAMA Oncology(2021)10.1001/jamaoncol.2021.3441

N/A

1.6DataRank · unranked

45 citations

Paul Frankel, Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh +15 more

Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1569

N/A

0DataRank · unranked

42 citations

Satyanarayana Rachagani, Seema Parte, Sushanta Halder, Parthasarathy Seshacharyulu, Prakash Kshirsagar +12 more

RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5576

N/A

0DataRank · unranked

1 citations

Hao Wang, Michael T. Schweizer, Michael A. Carducci, Channing J. Paller, Benjamin A. Teply +5 more

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4507

N/A

0DataRank · unranked

1 citations

Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou +15 more

Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression

Cancer Letters(2023)10.1016/j.canlet.2023.216468

N/A

0DataRank · unranked

22 citations

Diane Costanzo-Garvey, Benjamin A. Teply, Shawna Boyle, Gary Sommerville, Zachary T. Herbert +15 more

Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity

The Prostate(2023)10.1002/pros.24648

N/A

0DataRank · unranked

4 citations

Dipanwita Das, Negin Ziamiavaghi, Robin High, Kaustubh Datta, Benjamin A. Teply +1 more

Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5087

N/A

0DataRank · unranked

4 citations

Benjamin A. Teply, Su Jin Lim, Hao Wang, Shifeng Mao, William Kevin Kelly +10 more

Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer(2020)10.1016/j.bbcan.2020.188383

N/A

0DataRank · unranked

45 citations

Lei Xi, Kaustubh Datta, Anindita Das, Benjamin A. Teply, Surinder K. Batra +2 more

PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer

Cancer Letters(2024)10.1016/j.canlet.2024.217355

N/A

0DataRank · unranked

5 citations

Raghupathy Vengoji, Rama Krishna Nimmakayala, Parthasarathy Seshacharyulu, Balaji Perumalsamy, Zahraa Wajih Alsafwani +8 more